Here’s What They Aren’t Telling You About $117/mo GLP-1s

If you’ve seen the ads for $117/mo GLP-1 medications, your “scam radar” probably went off immediately. In a world where Ozempic and Mounjaro are famous for costing more than a monthly mortgage payment, a price tag near $100 feels like it has to be a bait-and-switch.

I decided to dig into the fine print of Fridays to see what the catch was. After talking to their team and looking at the clinical data, I realized there is a “secret” to that price—but it’s not a scam. 

Here is the “inside dirt” on how that $117 price point actually works and why it’s changing the game.

1. The “Price” Secret: You’re Bypassing the $1,000 “Brand Tax”

How can it be $117/mo when the pharmacy says $1,200? The answer is simpler than you think: most of us have been paying for a brand name, not just a formula.

The Reality: Fridays cuts out the massive pharmaceutical middlemen. By using compounded Semaglutide and Tirzepatide, they provide the same active ingredients found in the brand-name versions but without the $1,000 markup for patented plastic pens and billion-dollar marketing budgets. You are paying for the medicine and the science, not the corporate overhead.

2. It’s a Full Metabolic Clinic, Not Just a Prescription

What they “aren’t telling you” in the 30-second social media clips is that your membership isn’t just a transaction for a vial. It’s a complete support system designed to make sure the weight actually stays off.

The Reality: Fridays is a comprehensive health platform. While most people pay $117 just for a gym membership or a couple of therapy sessions, here that cost includes:

  • One-on-One Dietitians: To help you manage nutrition so you feel your best.
  • Movement Coaches: To build a fitness plan that actually works with your lifestyle.
  • Insurance Concierge: If you do want the brand-name pens, they have a dedicated team that fights your insurance company to try and get it covered for you.

3. The “Safety” Factor: Is it Legitimate?

Once you get past the price, the next question is always: Is this safe? This is where the “too good to be true” feeling usually stops, because the medical standards here are actually higher than many local clinics.

The Reality: Fridays is LegitScript Certified, which is the gold standard for online healthcare safety. You don’t just “buy” meds; you have a real consultation with a board-certified clinician who reviews your history and lab work. They only use state-licensed, regulated pharmacies to ensure that what’s in the vial is exactly what the doctor ordered. With a 4.7-star rating on Trustpilot, they have thousands of real-world success stories to back it up.

The Verdict: Is the $117/mo. Plan Worth It?

If you have $1,200 a month to burn, you can keep going to the local pharmacy. But if you want the same clinical results, a team of doctors in your pocket, and a price that doesn’t require a second mortgage, Fridays is the real deal. They’ve stripped away the “luxury” markup of weight loss and turned it into what it should be: Affordable, effective healthcare.

Ready to see the “secret” for yourself?

Take the 2-minute eligibility quiz at JoinFridays.com to see if you qualify for their GLP-1 programs and start your journey for a fraction of the pharmacy price.

Disclaimers:
Compounded drug products are not FDA approved. FDA does not evaluate compounded products for safety, effectiveness, or quality. Prescription products require an online consultation with a healthcare provider who will determine if a prescription is appropriate. Not available in all 50 states. Please visit our website for full details, applicable restrictions, and important drug safety information.
Fridays does not manufacture compounded medications. Actual product appearance and labeling of the medication you receive will differ from website images.
Low price based on 12 month subscription of compounded Semaglutide with March promotional savings. Valid through 3/31.

This post is sponsored by Fridays.

No Comments Yet

Leave a Reply

Your email address will not be published.